CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
Strategic Acquisition | CorMedix's $300M acquisition of Melinta Therapeutics promises portfolio diversification and near-term EPS accretion, reshaping its market position |
Financial Projections | Explore CorMedix's ambitious FY2025 guidance, projecting revenues of $305M-$330M and EBITDA of $150M-$170M, signaling strong growth potential |
DefenCath's Momentum | Delve into DefenCath's Q2 2025 sales of $39M and its potential expansion into the TPN market, highlighting CorMedix's focus on product development |
Analyst Outlook | Citizens Bank sets a $22 price target for CRMD, labeling it "MARKET OUTPERFORM" and underscoring the stock's potential upside |
Metrics to compare | CRMD | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCRMDPeersSector | |
---|---|---|---|---|
P/E Ratio | 17.3x | −4.0x | −0.7x | |
PEG Ratio | 0.09 | 0.15 | 0.00 | |
Price/Book | 4.0x | 2.0x | 2.6x | |
Price / LTM Sales | 7.3x | 1.7x | 3.4x | |
Upside (Analyst Target) | 80.8% | 138.0% | 35.5% | |
Fair Value Upside | Unlock | 11.3% | 3.3% | Unlock |